Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Nasopharyngeal Carcinoma 14Triple Negative Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 10Esophageal Squamous Cell Carcinoma 9Breast Neoplasms 8Colorectal Neoplasms 7Carcinoma, Renal Cell 7Small Cell Lung Carcinoma 6Neoplasms 6Advanced Solid Tumor 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Urinary Bladder Neoplasms 4Recurrence 4Carcinoma, Hepatocellular 4Stomach Neoplasms 3Solid Tumor 3Neoplasm Metastasis 3Liver Neoplasms 3Carcinoma, Transitional Cell 3Turcot syndrome 2Sarcoma 2Oropharyngeal Neoplasms 2Nasopharyngeal Neoplasms 2NSCLC 2Muscle Invasive Bladder Cancer (MIBC) 2Carcinoma, Squamous Cell 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2

Interventions

toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muscle-invasive Bladder Urothelial Carcinoma × toripalimab × 1 year × Clear all
NCT07279597 2025-12-19

A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

Tongji Hospital

Phase 2 Not yet recruiting
45 enrolled
Genitourinary

Muscle-invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡